Search
Binodenoson
go.drugbank.com/drugs/DB04853InvestigationalBinodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A2A receptor. This specificity allows Binodenoson to deliver - in a single injection - a more effective d...
Categories: Purinergic P1 Receptor AgonistsIstradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigationalIstradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTecadenoson
go.drugbank.com/drugs/DB04954InvestigationalTecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc.
Categories: Purinergic P1 Receptor AgonistsNamodenoson
go.drugbank.com/drugs/DB12885InvestigationalNamodenoson has been used in trials studying the treatment of Chronic Hepatitis C and Hepatocellular Carcinoma.
Categories: Purinergic P1 Receptor AgonistsAminophylline
go.drugbank.com/drugs/DB01223ApprovedInvestigationalAminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesLevodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalLevodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it i...
Mixtures: Duodopa, 20 mg/ml + 5 mg/ml, Gel zur intestinalen Anwendung, LEVODOPA P BENS AL 100/25Ticagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigationalTicagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y12 receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilin...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesAldesleukin
go.drugbank.com/drugs/DB00041ApprovedInvestigationalAldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 ge...
Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP3A InhibitorsGemtuzumab ozogamicin
go.drugbank.com/drugs/DB00056ApprovedInvestigationalGemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzuma...